RATIONALE: To determine the role of the endocannabinoid, 2-arachodonyl glycerol (2-AG), in the regulation of nausea and vomiting. OBJECTIVE: We evaluated the effectiveness of the potent selective monoacylglycerol lipase (MAGL) inhibitor, MJN110, which selectively elevates the endocannabinoid 2-AG, to suppress acute nausea and vomiting, as well as anticipatory nausea in rat and shrew models. METHODS: The rat gaping models were used to evaluate the potential of MJN110 (5, 10, and 20 mg/kg, intraperitoneally [IP]) to suppress acute nausea produced by LiCl and of MJN110 (10 and 20 mg/kg, IP) to suppress anticipatory nausea elicited by a LiCl-paired context. The potential as well of MJN110 (10 and 20 mg/kg, IP) to suppress vomiting and contextually elicited gaping in the Suncus murinus was evaluated. RESULTS: MJN110 suppressed acute nausea in rats, LiCl-induced vomiting in shrews and contextually-elicited anticipatory nausea in both rats (accompanied by elevation of 2-AG in the visceral insular cortex) and shrews. These effects were reversed by the CB1 antagonist/inverse agonist, SR141716. The MAGL inhibitor did not modify locomotion at any dose. An activity-based protein profiling analysis of samples of tissue collected from the visceral insular cortex in rats and whole brain tissues in shrews revealed that MJN110 selectively inhibited MAGL and the alternative 2-AG hydrolase, ABHD6. CONCLUSIONS: MAGL inhibition by MJN110 which selectively elevates endogenous 2-AG has therapeutic potential in the treatment of acute nausea and vomiting as well as anticipatory nausea, a distressful symptom that is resistant to currently available treatments.
RATIONALE: To determine the role of the endocannabinoid, 2-arachodonyl glycerol (2-AG), in the regulation of nausea and vomiting. OBJECTIVE: We evaluated the effectiveness of the potent selective monoacylglycerol lipase (MAGL) inhibitor, MJN110, which selectively elevates the endocannabinoid 2-AG, to suppress acute nausea and vomiting, as well as anticipatory nausea in rat and shrew models. METHODS: The rat gaping models were used to evaluate the potential of MJN110 (5, 10, and 20 mg/kg, intraperitoneally [IP]) to suppress acute nausea produced by LiCl and of MJN110 (10 and 20 mg/kg, IP) to suppress anticipatory nausea elicited by a LiCl-paired context. The potential as well of MJN110 (10 and 20 mg/kg, IP) to suppress vomiting and contextually elicited gaping in the Suncus murinus was evaluated. RESULTS:MJN110 suppressed acute nausea in rats, LiCl-induced vomiting in shrews and contextually-elicited anticipatory nausea in both rats (accompanied by elevation of 2-AG in the visceral insular cortex) and shrews. These effects were reversed by the CB1 antagonist/inverse agonist, SR141716. The MAGL inhibitor did not modify locomotion at any dose. An activity-based protein profiling analysis of samples of tissue collected from the visceral insular cortex in rats and whole brain tissues in shrews revealed that MJN110 selectively inhibited MAGL and the alternative 2-AG hydrolase, ABHD6. CONCLUSIONS:MAGL inhibition by MJN110 which selectively elevates endogenous 2-AG has therapeutic potential in the treatment of acute nausea and vomiting as well as anticipatory nausea, a distressful symptom that is resistant to currently available treatments.
Authors: Steven G Kinsey; Laura E Wise; Divya Ramesh; Rehab Abdullah; Dana E Selley; Benjamin F Cravatt; Aron H Lichtman Journal: J Pharmacol Exp Ther Date: 2013-02-14 Impact factor: 4.030
Authors: Jin Fu; Giovanni Bottegoni; Oscar Sasso; Rosalia Bertorelli; Walter Rocchia; Matteo Masetti; Ana Guijarro; Alessio Lodola; Andrea Armirotti; Gianpiero Garau; Tiziano Bandiera; Angelo Reggiani; Marco Mor; Andrea Cavalli; Daniele Piomelli Journal: Nat Neurosci Date: 2011-11-20 Impact factor: 24.884
Authors: Jonathan Z Long; Weiwei Li; Lamont Booker; James J Burston; Steven G Kinsey; Joel E Schlosburg; Franciso J Pavón; Antonia M Serrano; Dana E Selley; Loren H Parsons; Aron H Lichtman; Benjamin F Cravatt Journal: Nat Chem Biol Date: 2008-11-23 Impact factor: 15.040
Authors: Erin M Rock; Cheryl L Limebeer; Jordan M Ward; Arianne Cohen; Katherine Grove; Micah J Niphakis; Benjamin F Cravatt; Linda A Parker Journal: Psychopharmacology (Berl) Date: 2015-08-23 Impact factor: 4.530
Authors: Martin A Sticht; David J Lau; Catherine M Keenan; Jean-Baptiste Cavin; Maria Morena; Venkata Kiran Vemuri; Alexandros Makriyannis; Benjamin F Cravatt; Keith A Sharkey; Matthew N Hill Journal: Br J Pharmacol Date: 2018-08-22 Impact factor: 8.739
Authors: Karen Jaqueline Paredes-Ruiz; Karla Chavira-Ramos; Mario Orozco-Morales; Cimen Karasu; Alexey A Tinkov; Michael Aschner; Abel Santamaría; Ana Laura Colín-González Journal: Neurotox Res Date: 2021-11-06 Impact factor: 3.911
Authors: Kiri L Wills; Gavin N Petrie; Geneva Millett; Cheryl L Limebeer; Erin M Rock; Micah J Niphakis; Benjamin F Cravatt; Linda A Parker Journal: Neuropsychopharmacology Date: 2015-12-09 Impact factor: 7.853
Authors: Martin A Sticht; Cheryl L Limebeer; Benjamin R Rafla; Rehab A Abdullah; Justin L Poklis; Winnie Ho; Micah J Niphakis; Benjamin F Cravatt; Keith A Sharkey; Aron H Lichtman; Linda A Parker Journal: Neuropharmacology Date: 2015-11-02 Impact factor: 5.250
Authors: Linda A Parker; Cheryl L Limebeer; Erin M Rock; Martin A Sticht; Jordan Ward; Greig Turvey; Othman Benchama; Girija Rajarshi; JodiAnne T Wood; Shakiru O Alapafuja; Alexandros Makriyannis Journal: Psychopharmacology (Berl) Date: 2016-04-06 Impact factor: 4.530
Authors: Malte Feja; Martin P K Leigh; Ajay N Baindur; Justin J McGraw; Ken T Wakabayashi; Benjamin F Cravatt; Caroline E Bass Journal: Neuropharmacology Date: 2019-10-17 Impact factor: 5.250